Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 35585959.
- Also identified by DOI 10.1016/j.bonr.2022.101582 and PMC identifier 9109183.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab.